The role of the melanocortin system in the feeding effects of peripheral peptide YY ) and ghrelin was investigated using the agouti (A y /a) mouse as a model of abnormal melanocortin signalling. Furthermore, we examined whether the ectopic expression of agouti protein in A y /a mice results in complete MC4-R inhibition, by studying the effects of peripheral alpha-melanocyte-stimulating hormone (a-MSH) and leptin on food intake. DESIGN: Adult A y /a mice were studied in the pre-obese state (7-8 weeks) and obese state (14-15 weeks). Animals received PYY 3-36 (0.02 mmol/kg), NDP-a-MSH (0.2 mmol/kg), leptin (2 mmol/kg) (all 24 h fasted state) and ghrelin (0.2 mmol/kg) (fed state) by intraperitoneal (i.p.) injection. Age-matched A y /a controls received i.p. saline. A separate cohort of wild-type (WT), agematched controls received the same peptide dose or saline. Food intake was measured at 1, 2, 4, 8 and 24 h post-injection and compared in all four groups. Plasma leptin-, ghrelin-and PYY-like immunoreactivity (IR) were measured using radioimmunoassay (RIA). RESULTS: At 2 h post-injection, PYY 3-36 reduced food intake in pre-obese and obese A y /a mice, whereas ghrelin had no effect. Plasma ghrelin levels were significantly reduced in pre-obese and obese A y /a mice compared to WT controls. Peripheral administration of NDP-a-MSH and leptin acutely suppressed feeding (0-2 h) in pre-obese and obese A y /a mice. CONCLUSIONS: Responsiveness of pre-obese and obese A y /a mice to PYY suggests that the melanocortin system may not be essential for the anorectic effects of this peptide. Melanocortinergic antagonism by agouti protein in A y /a mice may be sufficient to block the effects of endogenous, but not exogenous PYY 3-36 , a-MSH and leptin. The mechanism underlying ghrelin resistance in A y /a mice may result from antagonism of hypothalamic melanocortin receptors-4 by agouti protein, supporting a role for the melanocortin system in mediating ghrelin's actions.
Introduction
A y /a mice have yellow hair, adult-onset obesity, hyperinsulinaemia and impaired glucose tolerance. 1 This phenotype is recapitulated by ectopic expression of agouti cDNA in transgenic mice. 2, 3 Agouti protein is a high-affinity antagonist at the melanocortin receptor-1 (MC1-R) and MC4-R. 4 Agouti protein antagonises MC1-Rs within the skin to produce yellow pigmentation, and in A y /a mice, antagonises MC4-Rs within the central nervous system (CNS), causing hyperphagia and obesity. 4 Consistent with this, MC4-R knockout mice exhibit a similar obesity syndrome, yet do not have yellow fur. 5 Agouti-related protein (AgRP), an endogenous homologue of agouti protein, selectively antagonises MC3-and MC4-Rs. 6 Overexpression of AgRP in transgenic mice produces an obese phenotype similar to that of MC4-R knockout or A y /a mice. 6, 7 AgRP is coexpressed with neuropeptide Y (NPY), another orexigenic signal, in neurones of the hypothalamic arcuate nucleus. 8, 9 Pro-opiomelanocortin (POMC), the precursor of the endogenous MC3-and MC4-R agonist alpha-melanocyte-stimulating hormone (a-MSH), is expressed in a separate population of arcuate neurons. 9 Leptin, the adipocytederived hormone, acts as a satiety factor to regulate feeding, 10 and both arcuate POMC neurones 11 and AgRP neurones 12 express the active form of the leptin receptor, Ob-R mRNA. Leptin is thought to regulate energy balance by influencing these two neuronal populations. Obese A y /a mice have reduced arcuate AgRP mRNA expression compared to pre-obese A y /a mice. 13 NPY mRNA expression in preobese A y /a mice is restricted to the arcuate nucleus; however, in obese A y /a mice, NPY mRNA is also expressed in the dorsomedial nucleus (DMN).
14 Mature obese A y /a mice are hyperleptinemic, due to an increased fat mass and are reported to be insensitive to exogenous, peripheral leptin. 15 Furthermore, young, lean A y / a mice, which have normal circulating leptin, are also resistant to exogenous leptin. 16 Melanocortinergic blockade by agouti protein in these mice therefore appears to antagonise the CNS effects of leptin. However, these conclusions of leptin resistance in A y /a mice are based on chronic studies of peripheral leptin administration, with daily measurements of body weight as the end point. 15, 16 Detailed analyses of food intake might provide further evidence for this hypothesis.
Recently, gut hormones have been implicated in the regulation of energy balance. Ghrelin, produced by the stomach, 17 has a potent orexigenic action when administered peripherally 18, 19 or directly into the CNS. 18, [20] [21] [22] Hypothalamic NPY and AgRP may be important in mediating the orexigenic effects of ghrelin. Ghrelin stimulates NPY release from hypothalamic explants in vitro 23 and coadministration of a Y1 or Y5 NPY receptor antagonist attenuates the orexigenic effect of centrally injected ghrelin. 21 Similarly, co-administration of anti-AgRP IgG and ghrelin into the CNS diminishes ghrelin's orexigenic effects.
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PYY 3-36 is produced by the endocrine cells of the gastrointestinal mucosa. 24 Recently, we have demonstrated that administration of PYY 3-36 both peripherally and into the arcuate nucleus inhibits food intake in rodents by modulating NPY and melanocortin systems within the arcuate nucleus. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] inhibits NPY/AgRP neurones via arcuate Y2 receptors, subsequently disinhibiting POMC neurones to cause a reduction in food intake. 25 Since ghrelin increases feeding via upregulation of hypothalamic NPY and AgRP, we hypothesised that in obese A y / a mice, with altered hypothalamic expression of these neuropeptides, peripheral ghrelin would produce different feeding responses compared to wild-type (WT) controls. Similarly, altered levels of hypothalamic NPY and AgRP mRNA in obese A y /a mice could result in resistance to peripheral PYY . Conversely, in pre-obese A y /a mice, with normal hypothalamic NPY and AgRP gene expression, ghrelin or PYY 3-36 administration should produce similar feeding responses to age-matched WT mice. Therefore, we examined the effects of peripheral injection of PYY and ghrelin on feeding in adult pre-obese (7-8 weeks) and obese (14) (15) Plasma leptin, ghrelin and PYY measurement Two cohorts of non-fasted A y /a and WT mice were studied, aged 7-8 weeks (pre-obese cohort) and 14-15 weeks (obese cohort), respectively. Mice were killed in the early-lightphase by inhalation of 99% CO 2 until respiration had just ceased. Whole blood was collected by cardiac puncture and mixed with 0.06 mg aprotinin (Bayer, Haywards Heath, UK) to prevent peptide degradation. Plasma was separated by centrifugation, frozen and stored at À201C until radioimmunoassay (RIA).
Anorectic and orexigenic peptides in agouti mice NM Martin et al All samples were assayed in duplicate. Mouse plasma leptin immunoreactivity (IR) was measured in 50 ml samples using a commercial RIA according to the manufacturer's instructions (Linco Research, St Charles, MO, USA). Ghrelinlike IR was measured with a specific and sensitive RIA. The antibody used (SC-10368 G102 Santa Cruz, CA, USA) recognises both octanoyl and des octanoyl ghrelin and does not crossreact with any known gastrointestinal or pancreatic peptide hormones. The antibody was used at a final dilution of 1:50 000. The 125 I-labelled ghrelin was prepared using
Bolton and Hunter reagent 28 (Amersham International, UK) and purified by reversed phase-high pressure liquid chromotography (RP-HPLC) using a linear gradient from 10 to 40% acetonitrile, 0.05% TFA over 90 min. The specific activity of ghrelin label was 48 Bq/fmol. The assay was performed in a total volume of 0.7 ml of 0.06 M phosphate buffer (pH ¼ 7.2) containing 0.3% BSA and incubated for 3 days at 41C before separation of antibody-bound label by dextran-coated charcoal. The assay detected changes of 25 pmol/l of plasma ghrelin with 95% confidence limit. The intra-assay coefficient of variation (at 5 fmol addition) was 10.5%. PYY-like IR was measured using a specific and sensitive RIA, as previously described. 29 
Statistical analysis
Results are given as mean7s.e.m. For feeding studies, comparisons were made between groups using one-way ANOVA with post hoc Fisher's Least Significant Difference method (Systat, Evanston, IL, USA) (Studies 2-5) or an unpaired Student's two-tailed t-test (Study 1 and Study 6). Study 3. Effects of a-MSH on food intake in pre-obese and obese A y /a mice Studying the pre-obese cohort, a-MSH reduced food intake at 2 h post-injection, in both genotypes (Figure 3a) . Food intake was unchanged in all four groups at 24 h post-injection. In fasted, obese A y /a mice, 2 h food intake was also suppressed by a-MSH compared to saline (Figure 3b ). There was a significant difference in food intake between fasted, salineinjected obese A y /a and WT controls until 8 h post-injection Anorectic and orexigenic peptides in agouti mice NM Martin et al Study 5. Effects of ghrelin on food intake in pre-obese and obese A y /a mice Our previous work in rodents has demonstrated that i.p. ghrelin stimulates feeding at 1 h post-injection, but not at subsequent time points. 18 Consistent with this, ghrelin increased food intake 1 h post-injection in freely feeding WT mice of both pre-obese and obese cohorts (Figure 5a and b). This stimulatory effect on feeding was not observed in either cohort at further time-points. However, ghrelin did not significantly alter feeding in either pre-obese or obese non-fasted A y /a mice (Figure 5a and b) at any time point.
Notably, since ghrelin or saline injections were administered in the fed state, food intake was similar in obese A y /a mice and WT littermates following an i.p. saline injection.
Study 6. Plasma leptin, ghrelin and PYY concentrations in pre-obese and obese A y /a mice Consistent with previous findings, 30,31 plasma leptin was significantly increased in obese A y /a mice compared to agematched WT controls ( Figure 6 ). However, in pre-obese A y /a mice, plasma leptin was five times higher than in WT controls ( Figure 6 ). Therefore, pre-obese mice, despite having the same body weight as WT controls, are likely to have increased body adiposity. In both pre-obese and obese A y /a mice, plasma ghrelin concentration was significantly reduced compared to agematched WT controls ( Figure 6 ). There was no difference in plasma ghrelin between pre-obese and obese A y /a mice.
Plasma PYY was similar in fasted pre-obese A y /a mice compared to WT controls ( Figure 6 ). However, plasma PYY in fasted obese A y /a mice was increased by almost 50% compared to age-matched WT controls ( Figure 6 ).
Discussion
These studies show that obese A y /a mice are more sensitive to the effects of fasting than WT mice or pre-obese A y /a mice. It has previously been reported that obese A y /a mice react with a disproportionate inhibition of feeding following stresses such as restraint, handling and i.p. injection, although the cause of this is unknown. 32 In the current studies, fasting and i.p. injection may be sufficient stresses to reduce feeding in obese A y /a mice. I.p. saline-injected fasted obese A y /a mice consistently ate less than WT controls, although this effect did not occur in the fed state. Therefore, it is likely that the stress of a 24 h fast, rather than that of an i.p. saline injection, inhibits feeding in obese A y /a mice. Interestingly, 
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NM Martin et al response as food intake was significantly reduced compared to saline-injected obese A y /a controls. This is the first report of the effects of peripherally administered PYY 29 However, obesity in A y /a mice is secondary to abnormal hypothalamic signalling, whereas obesity in humans is multifactorial. An elevation in plasma PYY may be an appropriate compensatory signal to the CNS to attempt to normalise energy homeostasis. This is in accordance with pre-obese A y /a mice having normal plasma PYY levels.
PYY inhibits NPY/AgRP neurones, disinhibiting POMC neurones and therefore stimulating a-MSH release. 25 In A y /a mice, agouti protein competitively antagonises MC4-Rs and hence acts downstream of POMC neurones. However, this antagonism did not alter the anorectic actions of exogenous PYY in A y /a mice. Similarly, peripheral injection of either a-MSH or leptin, both of which exert their effects through activation of CNS MC3-and MC4-Rs, 33 reduced feeding in pre-obese and obese A y /a mice. These findings may reflect sufficient melanocortinergic antagonism by agouti protein in A y /a mice to block the effects of endogenous, but not exogenous PYY , a-MSH and leptin. Alternatively, PYY 3-36 , a-MSH and leptin may reduce food intake through a mechanism involving an alternative receptor not antagonised by agouti protein, such as the MC3-R. 4 A possible role for the MC3-R in the regulation of food intake is also supported by the observation that obese A y /a mice have reduced food intake following CNS injection of MTII, a MC3-R and MC4-R agonist. 34 Our findings that pre-obese and obese A y /a mice are sensitive to peripheral leptin is in contrast to previous studies. 15, 16, 27 However, in several of these studies, 'leptin resistance' was demonstrated by measuring daily body weight. 15, 16 A study of feeding responses of obese A y /a mice to peripheral leptin concentrated on average daily food intake and involved smaller animal numbers than the current study. 27 Similarly, the effects of peripheral a-MSH on energy balance in A y /a mice are limited to studying body weight rather than food intake. 26 Our data show that the effects of peripheral a-MSH and leptin on food intake in pre-obese A y /a mice are short-lived, with no effects on 24 h food intake. Therefore, these short-lived alterations in feeding may not influence daily body weight. However, in obese A y /a mice, the anorectic effects of leptin are observed at 24 h post-injection. In support of our findings, chronic peripheral administration of leptin in transgenic mice ectopically expressing agouti protein transiently reduced daily food intake without a simultaneous reduction in body weight. 35 Hence, chronic leptin administration to A y /a mice may acutely reduce feeding without altering body weight.
Conversely, we have observed that both pre-obese and obese A y /a mice are resistant to the orexigenic effects of peripherally injected ghrelin. Arcuate NPY neurones, rather than those at other hypothalamic sites, appear to mediate the actions of peripheral ghrelin on feeding. 36 Owing to the insensitivity of both pre-obese and obese A y /a mice to peripheral ghrelin, AgRP, rather than NPY, could be important in mediating ghrelin's orexigenic effects. AgRP is an important mediator in ghrelin-induced feeding, 21 and NPY-deficient mice have a normal feeding response to peripherally administered ghrelin. 20 Obese A y /a mice, similar in age to those in the current study, have reduced arcuate AgRP mRNA expression 13 and peripheral ghrelin may be unable to sufficiently upregulate AgRP to stimulate feeding. However, pre-obese A y /a mice have similar arcuate AgRP mRNA levels to WT littermates, 13 yet are also insensitive to peripheral ghrelin. Alternatively, in pre-obese and obese A y /a mice, chronic antagonism of hypothalamic MC4-Rs by agouti protein could prevent a further upregulation of AgRP by ghrelin.
Resistance of A y /a mice to exogenous peripheral ghrelin administration is not secondary to elevated circulating ghrelin, since we have shown that both pre-obese and obese A y /a mice have low plasma ghrelin. This is consistent with previous studies of murine 38 and human, 29,39-42 models of obesity. A reduction in plasma ghrelin in human obesity is believed to be compensatory rather than causative. Resistance to ghrelin in obesity would be another compensatory mechanism to prevent further over-eating. The observed reduction in plasma ghrelin concentrations in pre-obese and obese A y /a mice could be secondary to their increased plasma leptin levels, since leptin has been shown to negatively regulate ghrelin. 43 Although a previous study has shown that pre-obese A y /a mice do not have elevated plasma leptin, 16 this described much younger mice than those used in the current study.
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In conclusion, we have shown that pre-obese and obese A y / a mice are sensitive to the anorectic effects of peripheral PYY . This is consistent with our recent findings that obese humans are sensitive to exogenous PYY . 29 In contrast, neither pre-obese nor obese A y /a mice respond to the orexigenic peptide ghrelin, despite having low circulating plasma ghrelin. In obese A y /a mice, the mechanism underlying resistance to ghrelin is unclear, but could involve altered hypothalamic NPY and/or AgRP signalling. Antagonism of CNS MC4-Rs by ectopic agouti expression could also inhibit ghrelin-induced feeding. This supports a role for the melanocortin system in mediating ghrelin's effects. Since PYY inhibits feeding in A y /a mice, the MC4-R may not be essential for the anorectic effects of this peptide. Our data show that obesity in the A y /a mouse is associated with ghrelin resistance and hence it would be interesting to study the effects of peripheral ghrelin in obese humans. However, the responsiveness of obese A y /a mice to PYY supports this peptide as a potential antiobesity agent. 29 
